pemvidutide vs survodutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline
pemvidutide
Developed by Altimmune
NCT05989711 · Phase 2 · completed
IMPACT was a randomized, quadruple-blind, placebo-controlled Phase 2b in 212 patients with MASH with two biopsy co-primary endpoints. MASH resolution was met at both doses; fibrosis improvement did not reach statistical significance, so the primary comparison was only partly met and the grade is moderate.
Next expected readout: December 2028 · NCT07795164 (registry estimate)
Reported efficacy
Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis (24 weeks); Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) (24 weeks); Incidence of Treatment Emergent Adverse Events (52 weeks): Co-primary endpoints at week 24 (ITT): MASH resolution without fibrosis worsening 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% placebo (p<0.0001); fibrosis improvement without MASH worsening 31.8% and 34.5% vs 25.9%, not statistically significant (HCPLive, 2025-06-26). (mixed)
Result source: NCT05989711
survodutide
Developed by Boehringer Ingelheim under a licence from Zealand Pharma
NCT06309992 · Phase 3 · completed
This phase 3 trial randomly assigned 216 adults with obesity and at-risk MASLD (2:1) to weekly survodutide 6.0 mg or placebo, with double-blind treatment for 48 weeks. The first co-primary endpoint was a reduction of at least 30% in liver fat on MRI: 84.2% of survodutide patients reached it against 24.3% on placebo (P<0.0001). The second co-primary endpoint was body weight change: -12.2% against -1.0% (P<0.0001). Both co-primary endpoints were met, so the result is met. The figures come from the peer-reviewed Nature Medicine paper.
Next expected readout: April 2029 · NCT07850063 (registry estimate)
Reported efficacy
Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] (at baseline, at week 48); Relative change (%) in body weight [kg] from baseline to Week 48 (at baseline, at week 48): Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. (met)
Result source: NCT06309992
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | pemvidutide | survodutide |
|---|---|---|
| MASH resolution without fibrosis worsening | 52.1% vs 19.1%a+33 vs placeboNCT059897111 other result
| —Not posted · NCT06309992 |
| Fibrosis stage, change | —Trial running · NCT07795164 | —Not posted · NCT06309992 |
| Liver fat (MRI-PDFF), change | —Trial running · NCT07795164 | -13.0% vs -1.9%−11.1 vs placeboNCT0477127311 other results
|
| ALT, change | —Trial running · NCT07795164 | —Not posted · NCT06309992 |
MASH resolution without fibrosis worsening
- pemvidutide
- 52.1% vs 19.1%a+33 vs placeboNCT05989711
1 other result
- 59.1% vs 19.1% NCT05989711
- survodutide
- —Not posted · NCT06309992
Fibrosis stage, change
- pemvidutide
- —Trial running · NCT07795164
- survodutide
- —Not posted · NCT06309992
Liver fat (MRI-PDFF), change
- pemvidutide
- —Trial running · NCT07795164
- survodutide
- -13.0% vs -1.9%−11.1 vs placeboNCT04771273
11 other results
- -12.5% vs -1.6% NCT04771273
- -64.3% vs -7.3% NCT04771273
- -62.0% vs -5.7% NCT04771273
- -12.8% vs -1.9% NCT04771273
- -12.4% vs -1.6% NCT04771273
- -62.8% vs -7.3% NCT04771273
- -60.8% vs -5.7% NCT04771273
- -10.5% vs -1.9% NCT04771273
- -10.7% vs -1.6% NCT04771273
- -50.9% vs -7.3% NCT04771273
- -52.2% vs -5.7% NCT04771273
ALT, change
- pemvidutide
- —Trial running · NCT07795164
- survodutide
- —Not posted · NCT06309992
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. pemvidutide: 0 of 4 rows · survodutide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | pemvidutide | survodutide |
|---|---|---|
| Dropout rate | — | —6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results24%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 13.7%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 15.1%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | —6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results16%6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 12.3%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence 11%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 9.6%6.0 mga NCT04771273 · Phase 2 · registry result, not featured evidence show 5 more results—6.0 mg NCT04771273 · Phase 2 · registry result, not featured evidence 10.1%4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence —4.8 mg NCT04771273 · Phase 2 · registry result, not featured evidence 5.4%2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence —2.4 mg NCT04771273 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | 6.0 mga nausea 63.5% (placebo 27.8%) diarrhoea 55.8% (placebo 25.3%) constipation 28.8% (placebo 17.7%) NCT04771273 · Phase 2 · registry result, not featured evidence show 2 more results4.8 mg nausea 66.7% (placebo 27.8%) diarrhoea 53.6% (placebo 25.3%) vomiting 47.8% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence 2.4 mg nausea 64.5% (placebo 27.8%) diarrhoea 40.9% (placebo 25.3%) vomiting 40.9% (placebo 7.6%) NCT04771273 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
pemvidutide
show 1 more result
survodutide
show 5 more results
show 5 more results
show 11 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pemvidutide's landscape · survodutide's landscape